Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
A groundbreaking materials — engineered bone marrow (eBM) — has the potential to enhance therapy for osteosarcoma, a malignant bone most cancers with...
Newswise — In 2022, Alaggio and colleagues revised the WHO Classification of Haematolymphoid Tumors leading to elimination of the provisional diagnostic classes of...
